Grifols, S.A. (GRFS)
NASDAQ: GRFS · Real-Time Price · USD
7.97
-0.06 (-0.75%)
At close: Mar 12, 2026, 4:00 PM EDT
7.85
-0.12 (-1.51%)
Pre-market: Mar 13, 2026, 7:44 AM EDT
Grifols Revenue
In the year 2025, Grifols had annual revenue of 1.23B EUR, down -79.02%.
Revenue (ttm)
1.23B EUR
Revenue Growth
-79.02%
P/S Ratio
0.74
Revenue / Employee
51,765 EUR
Employees
23,737
Market Cap
6.57B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.23B | -4.63B | -79.02% |
| Dec 31, 2022 | 5.86B | 517.88M | 9.70% |
| Dec 31, 2020 | 5.34B | 241.35M | 4.73% |
| Dec 31, 2019 | 5.10B | 2.36B | 85.97% |
| Dec 31, 2013 | 2.74B | 120.79M | 4.61% |
| Dec 31, 2012 | 2.62B | 1.63B | 164.55% |
| Dec 31, 2010 | 990.73M | 77.54M | 8.49% |
| Dec 31, 2009 | 913.19M | 98.88M | 12.14% |
| Dec 31, 2008 | 814.31M | 111.02M | 15.79% |
| Dec 31, 2007 | 703.29M | 54.87M | 8.46% |
| Dec 31, 2006 | 648.42M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| Sanofi | 54.85B |
| Novo Nordisk | 48.59B |
| Bristol-Myers Squibb Company | 48.19B |
| GSK plc | 43.97B |
| Amgen | 36.75B |
| Gilead Sciences | 29.44B |
GRFS News
- 14 hours ago - Media Advisory: Press Conference Regarding Tragic Deaths After Plasma Harvesting at Grifols' Sites - GlobeNewsWire
- 14 days ago - Grifols SA (GRFS) (Full Year 2025) Earnings Call Highlights: Strong Revenue Growth Amidst ... - GuruFocus
- 14 days ago - Full Year 2025 Grifols SA Earnings Call Transcript - GuruFocus
- 14 days ago - Grifols (GRFS) Projects Strong Financial Performance by 2026 - GuruFocus
- 14 days ago - Grifols (GRFS) Exceeds Revenue Expectations and Gains Credit Rating Upgrades - GuruFocus
- 14 days ago - Grifols doubles net profit in 2025, driven by revenues - Reuters
- 5 months ago - Spanish court summons Gotham City founder in Grifols share price probe - Reuters
- 9 months ago - XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology - GlobeNewsWire